E7050

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cancer

Conditions

Cancer

Trial Timeline

Mar 1, 2009 → —

NCT ID

NCT00869895

About E7050

E7050 is a phase 1 stage product being developed by Eisai for Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00869895. Target conditions include Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Cancer were approved

Approved (20) Terminated (4) Active (0)

✅arzoxifeneEli LillyApproved

✅EnzalutamideAstellas PharmaApproved

✅Enzalutamide + Androgen deprivation therapy (ADT)Astellas PharmaApproved

✅Enzalutamide + Abiraterone + Placebo for Enzalutamide + PrednisoneAstellas PharmaApproved

✅EnzalutamideAstellas PharmaApproved

✅Enzalutamide + FlutamideAstellas PharmaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01428141	Phase 1	Completed	Sep 1, 2011	Jul 1, 2013	Solid Tumor
NCT02533102	Phase 1	Completed	Nov 1, 2010	Feb 1, 2011	Healthy Subjects
NCT00921869	Phase 1	Completed	Oct 1, 2009	Jun 1, 2011	Solid Tumors
NCT00869895	Phase 1	Completed	Mar 1, 2009	—	Cancer

Competing Products

20 competing products in Cancer

See all competitors

Product	Company	Stage	Hype Score
mFOLFOX regimen + Mitazalimab	Alligator Bioscience AB	Phase 2/3	35
Intratumoral Mitazalimab + Intratumoral Nivolumab	Alligator Bioscience AB	Phase 1	26
mRNA-2416	Moderna	Phase 2	0
Doxorubicin Hydrochloride Liposome Injection	Dr. Reddy's Laboratories	Phase 1	26
E7389	Eisai	Phase 1	29
Veliparib	AbbVie	Phase 2	27
AK-105	Akeso	Phase 1	29
XL820	Exelixis	Phase 1	26
Lymphoseek	Navidea Biopharmaceuticals	Phase 3	30
Lymphoseek	Navidea Biopharmaceuticals	Phase 3	30
ALT-P7 (HM2-MMAE)	Alteogen	Phase 1	29
pegylated liposomal doxorubicin (PLD) + PD-1	CSPC Pharmaceutical Group Limited	Phase 2	31
Biomarkers blood, urine and microbiota samples	Eli Lilly	Pre-clinical	30
gemcitabine + paclitaxel + bevacizumab	Eli Lilly	Phase 2	35
pemetrexed	Eli Lilly	Phase 2	27
LY3300054 + Prexasertib	Eli Lilly	Phase 1	29
BBP-398 with nivolumab	BridgeBio Pharma	Phase 1	18
Cetuximab + Oxaliplatin + Capecitabine	Eli Lilly	Phase 2	35
Necitumumab + Gemcitabine + Carboplatin	Eli Lilly	Phase 2	27
Gemcitabine + Adriamycine + Paclitaxel	Eli Lilly	Phase 2	35